MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Stock Quote (indian pharma)
- BIOCON
BIOCON Share Price (BICN)
Here is the latest stock price and chart of BIOCON . For more details, see the BIOCON company fact sheet and quarterly results. For a sector overview, read our pharmaceuticals sector report.
Last Chance: Grab Your Free Spot for Rahul Shah's Lazy Millionaire Summit
| Live BSE Quotes | Jan 21, 2022 (Close) | ||
|---|---|---|---|
| Price (Rs)376.60 | Open (Rs) 363.00 | High (Rs) 382.45 | Low (Rs) 356.05 |
| % Change3.49 | Volume 312,016 | Value (Rs) 116,845,539 | 52-Week H/L 456.00 / 314.90 |
| Live NSE Quotes | Jan 21, 2022 (Close) | ||
|---|---|---|---|
| Price (Rs)377.10 | Open (Rs) 364.00 | High (Rs) 382.50 | Low (Rs) 356.00 |
| % Change3.54 | Volume 9,950,400 | Value (Rs) 3,727,679,793 | 52-Week H/L 455.00 / 314.80 |
| Change | |||||
|---|---|---|---|---|---|
| 1 Day 3.49% | 1 Month 7.54% | 3 Months 9.13% | 1 Year -14.79% | 5 Years (CAGR)* 17.73% | 10 Years (CAGR)* 23.75% |
* Compound Annual Growth Rate
| Valuation | ||||
|---|---|---|---|---|
| EPS (Rs)* 7.73 | P/E Ratio (x) 48.70 | Market Cap (Rs m) 452,145.96 | P/BV (x) 6.05 | Dividend Yield (%) 0.00 |
| *Trailing 12 months earnings, excluding extraordinary / exceptional items. | BSE Sensex | CNX Nifty |
- Charts
-
S&P BSE SENSEX 
PERIOD - Advanced Charts new
- Charts by TradingView
BIOCON Share Price Today:
BIOCON last traded price was up 3.5% to Rs 376.6 on the BSE. On the NSE, BIOCON last traded price was up 3.5% to Rs 377.1. The total volume of shares traded was 10.3 m.
Overall, the broader S&P BSE HEALTHCARE Index was down by 1.4%. And the benchmark S&P BSE SENSEX was at 59,037.2 (down 0.7%).
Over the last 30 days, the BIOCON share price is up 7.1%. And over the last one year, BIOCON share price is down 16.3%.
The current market capitalisation of BIOCON stands at Rs 452,145.96 m. For more information, check out the list of top 100 companies in India in terms of market cap.
As of December 2021, company promoters held 60.64% stake in BIOCON , with no shares having been pledged. To know more, check out the latest shareholding pattern of BIOCON .
What else is happening in the markets today? Dig in...
- TRACK NOW:
- Most Active Stocks Rs 0 to 10
- Most Active Stocks Rs 10 to 20
- Top Gainers Today BSE A Group
- Top Gainers Today NSE Above Rs 20
- Top Gainers Today BSE Above Rs 20
- Top Gainers Today BSE Sensex
- Top Gainers Today BSE Small Cap
- Top Gainers Today BSE 500
- Top Losers Today BSE A Group
- Most Active Stocks Rs 1 to 2
- Top Losers Today NSE Above Rs 20
- Most Popular Stocks BSE 30
- TRENDING ON EQUITYMASTER:
- Warren Buffett - The Value Investor
- Your Ultimate Guide to Penny Stock Investing
- How to Invest in Gold
- Basics of Value Investing
- Benjamin Graham
- The Best Bluechip Stocks to Buy
- How to Invest in Silver
- The Best Small-cap Stocks to Buy
- 10 Rules for Successful Long-Term Investing
- How to Invest in the Share Market
- Best Stocks to Buy Today
- How to Use P/E for Successful Investing
- How to Find Undervalued Stocks
- Differences Between Trading and Investing
- SWOT Analysis for Stocks
- The Best Dividend Stocks to Buy
Today's Market
Sensex Sheds 427 Points, Nifty Ends Near 17,600; Bajaj Finserv, Tata Steel & Tech Mahindra Top Losers(Closing)
Indian share markets witnessed negative trading activity throughout the day today and ended on a weak note.
Related Views On News
BIOCON Announces Quarterly Results (2QFY22); Net Profit Up 4.9% (Quarterly Result Update)
Oct 26, 2021 | Updated on Oct 26, 2021For the quarter ended September 2021, BIOCON has posted a net profit of Rs 2 bn (up 4.9% YoY). Sales on the other hand came in at Rs 18 bn (up 5.2% YoY). Read on for a complete analysis of BIOCON 's quarterly results.
BIOCON 2020-21 Annual Report Analysis (Annual Result Update)
Aug 10, 2021 | Updated on Aug 10, 2021Here's an analysis of the annual report of BIOCON for 2020-21. It includes a full income statement, balance sheet and cash flow analysis of BIOCON . Also includes updates on the valuation of BIOCON .
BIOCON Announces Quarterly Results (1QFY22); Net Profit Down 4.0% (Quarterly Result Update)
Jul 26, 2021 | Updated on Jul 26, 2021For the quarter ended June 2021, BIOCON has posted a net profit of Rs 2 bn (down 4.0% YoY). Sales on the other hand came in at Rs 18 bn (up 3.9% YoY). Read on for a complete analysis of BIOCON 's quarterly results.
Sun Pharma vs Dr Reddy's: Which is Better? (Views On News)
Dec 16, 2021In an extremely competitive market, two pharma companies are competing against each other to grab the top spot.
5 Stocks to Watch Out for Amid the Omicron Outbreak (Views On News)
Dec 3, 2021As the new variant of Covid-19 emerges, keep an eye on these stocks.
More Views on NewsMost Popular
10 Indian Companies with the Fastest Growth in Dividend Payouts... (Views On News)
Jan 10, 2022These companies have been consistently paying higher dividends for several years.
Tata Steel vs SAIL: Which Stock is Better? (Views On News)
Jan 13, 2022With government initiatives set to boost the steel sector, find out who has a better chance of coming out on top.
Watch Out for these 4 Indian Companies Betting Big on EV Supply Chain (Views On News)
Jan 11, 2022The upside in supply chain players could be huge but a delay in the transition to EVs, or any policy related hiccups could end the momentum.
Tech Mahindra's CTC Acquisition: Too Expensive? (Views On News)
Jan 18, 2022Tech Mahindra's acquisition of European IT-company fails to excite investors.
These 5 Penny Stocks are Held by Rakesh Jhunjhunwala. Worth a Look? (Views On News)
Jan 18, 2022Rakesh Jhunjhunwala is holding these penny stocks in his portfolio for several years now.
MoreOUR TOP 5 IDEAS
- Free Report: Multibagger Stock Ideas 2022
- Are You Making One of These 15 Costly Mistakes While Investing. Learn more!
- Covid-19 Proof Multibagger Stocks - Download this FREE Report Now
- Free Report: How to Profit from Sensex 100,000
- No Guessing, No Hunches, and No Missed Trends Ever! Join Us on YouTube Now.
TRACK BIOCON
- Track your investment in BIOCON with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON BIOCON
BIOCON - ADCOCK INGRAM COMPARISON
COMPARE BIOCON WITH
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
FOLLOW
APP
EQUITYMASTER SUPPORTS
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited (Research Analyst) 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.